Modality
ASO
MOA
BTKi
Target
APOC3
Pathway
Neuroinflam
Crohn'sCF
Development Pipeline
Preclinical
~Jan 2012
→ ~Apr 2013
Phase 1
~Jul 2013
→ ~Oct 2014
Phase 2
~Jan 2015
→ ~Apr 2016
Phase 3
~Jul 2016
→ ~Oct 2017
NDA/BLA
~Jan 2018
→ ~Apr 2019
Approved
Jul 2019
→ Sep 2028
ApprovedCurrent
NCT04553564
690 pts·CF
2019-07→2025-07·Not yet recruiting
NCT05072310
2,213 pts·CF
2022-08→2028-09·Recruiting
2,903 total pts1 indication
CompletedCurrentUpcoming
Catalysts (2)
2025-07-258mo agoPh3 Readout· CF
2028-09-202.5y awayPh3 Readout· CF
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Approved
Not yet…
Approved
Recruit…
Catalysts
Ph3 Readout
2025-07-25 · 8mo ago
CF
Ph3 Readout
2028-09-20 · 2.5y away
CF
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04553564 | Approved | CF | Not yet recr... | 690 | ACR20 |
| NCT05072310 | Approved | CF | Recruiting | 2213 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 |